Use of Personal Fitness Device in Adult (> 21 Years Old) Patients With Cystic Fibrosis
1 other identifier
interventional
21
1 country
1
Brief Summary
Approximately half of the variation in the presentation and disease status of patients with Cystic Fibrosis (CF) is secondary to non-genetic variables.\[1\] These include household income, compliance with therapy, second hand smoke exposure and possibly exercise (although exercise has less evidence to support its influence on disease status). Recently increased attention has been focused on the role of exercise and quality of life for patients with CF. This study will evaluate the role of exercise in relation to the patient's perception of their quality of life. The primary outcome will be the overall change in the patient's Cystic Fibrosis Questionnaire - Revised (CFQ-R) over a one year period during which the participants are encouraged to exercise and use a personal fitness device to track their exercise. This is a prospective single group non-blinded study. Participants will be asked to wear a personal fitness device for 11-13 months. The change in CFQ-R score is the primary outcome and other secondary outcomes will include; (1) exacerbations of cystic fibrosis (through use of antibiotics), (2) change in subject's FEV1, (3) inpatient admission rates, (4) change in BMI and (5) change in 6 minute walk test. The study will take place at the Adult CF Clinic on the University of Oklahoma Health Sciences Center campus.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable quality-of-life
Started Apr 2017
Typical duration for not_applicable quality-of-life
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 17, 2017
CompletedStudy Start
First participant enrolled
April 18, 2017
CompletedFirst Posted
Study publicly available on registry
April 20, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2019
CompletedFebruary 15, 2024
February 1, 2024
1.8 years
April 17, 2017
February 13, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Change in quality of life for individuals with CF using a personal fitness device
Will be measured using the CFQ-R questionnaire (a standard questionnaire for CF patients)
Will be completed upon enrollment and at 6 months and 12 months
Secondary Outcomes (1)
Walking distance
This will be done upon enrollment, 6 months and 12 months
Study Arms (1)
Exercise Study Group
EXPERIMENTALAll subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
Interventions
Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
Eligibility Criteria
You may qualify if:
- diagnosis of CF,
- age of 21 or older,
- willingness to consider some type of routine exercise,
- BMI above 18 if female and above 20 for males,
- willing to wear personal fitness device daily and
- not already preforming daily exercise routinely
You may not qualify if:
- patients who are unable or unwilling to understand and sign consent for this study,
- patients who the study physicians determine it would not be safe to ask them to exercise,
- patients who are not expected to survive over the next 12 months,
- patients who are non-compliant and will not comply with study visits and procedures,
- patients currently participating in other research trials,
- patients who have had an acute exacerbation of their cystic fibrosis (treatment with oral or IV antibiotics) within the last 30 days,
- patients with significant room air hypoxia who require more than 4 liters by nasal cannula to improve oxygenation to more than 90%.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Karen S Allen, MD
OUHSC
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 17, 2017
First Posted
April 20, 2017
Study Start
April 18, 2017
Primary Completion
February 1, 2019
Study Completion
February 1, 2019
Last Updated
February 15, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share
Initial data analysis was clear that study completion would not lead to a statistically significant difference in the primary outcome. Data are available and may be obtained through written request to the PI.